Dr. Nigel Rawson

President, Eastlake Research Group

Dr. Nigel Rawson is a pharmacoepidemiologist, pharmaceutical policy researcher, and President of Eastlake Research Group in Oakville, Ontario. Educated in the United Kingdom, he holds an MSc in statistics and a PhD in pharmacoepidemiology. Dr. Rawson has performed epidemiologic studies of the use of drugs and their outcomes for over 35 years and published more than 120 book chapters and articles in peer-reviewed journals. He is also the author of the monograph “Drug Safety: Problems, Pitfalls and Solutions in Identifying and Evaluating Risk” published by Friesenpress.

Dr. Rawson held academic research positions in the United Kingdom until the end of 1989 and subsequently held professorships at the University of Saskatchewan and Memorial University of Newfoundland in Canada. His research activities focused on population-based studies of the use and safety of drugs using administrative healthcare utilization data and the evaluation of issues impacting access to new drugs. Dr. Rawson has also been a senior researcher in an independent research centre in one of the United States’ largest health insurers, where he collaborated with the Food and Drug Administration on drug safety studies, and GlaxoSmithKline’s only epidemiologist in Canada providing advice and analysis for the company’s current and developing medicines and vaccines. Dr. Rawson established Eastlake Research Group in 2012 with a mission to create data-driven responses to pharmaceutical and health policy issues.

Recent Research by Dr. Nigel Rawson

— Jul 17, 2014
Printer-friendly version

The organization that reviews oncology medicines in Canada may unnecessarily delay approvals while cancer patients suffer, finds a new study by Nigel Rawson. The study, Has pCODR Improved Access to Oncology Drugs?, spotlights the pan-Canadian Oncology Drug Review (pCODR), which recommends new oncology drugs to the provinces and territories (excluding Quebec) after clinical and cost-effectiveness assessments. The pCODR was established in 2010.

— Nov 7, 2013
Printer-friendly version

Slow regulatory and reimbursement approvals in Canada are affecting cancer survival.

— Jul 25, 2012
Printer-friendly version

Cancer is the leading cause of premature death in Canada and the numbers of new cases of several major cancers have remained relatively stable. New, better treatments are needed as soon as they can be introduced. This study compares the number of new oncology drugs approved by each agency and their review times.